The global postmenopausal osteoporosis treatment market size accounted for USD 12.8 billion in 2024, grew to USD 13.48 billion in 2025 and is projected to surpass around USD 21.46 billion by 2034, representing a healthy CAGR of 5.30% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Postmenopausal Osteoporosis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Postmenopausal Osteoporosis Market, by Drug Type, 2024-2034
8.1.1. Bisphosphonates
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Vitamin D3
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Estrogen Agonist/Antagonist
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Hormone Replacement Therapy
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Parathyroid Hormone Therapy
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Postmenopausal Osteoporosis Market, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1. Amgen Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Eli Lilly and Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis International AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Gilead Sciences, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Teva Pharmaceutical Industries Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Pfizer Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. GlaxoSmithKline plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Roche Holding AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Johnson & Johnson
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample